Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model
Open Access
- 1 July 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (13) , 4559-4567
- https://doi.org/10.1158/1078-0432.ccr-03-0325
Abstract
Purpose: It is established that bisphosphonates (BPs), specific inhibitors of osteoclasts, have beneficial effects on bone metastases of breast cancer. In addition, recent studies have reported that BPs have anticancer effects and suppress visceral metastases, too. However, the results of clinical studies are still conflicting. In the present study, we examined the effects of the BP zoledronic acid (ZOL), one of the most potent BPs currently available, on visceral metastases of breast cancer using an animal model in which mouse breast cancer cells 4T1/luc implanted at the orthotopic mammary fat pad spontaneously metastasize to multiple organs including bone, lung, and liver in female BALB/c mice.Keywords
This publication has 26 references indexed in Scilit:
- Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancerInternational Journal of Cancer, 2003
- Critical determinants of metastasisSeminars in Cancer Biology, 2002
- Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic AcidThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Bisphosphonates Induce Breast Cancer Cell Death In VitroJournal of Bone and Mineral Research, 2000
- A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer PatientsJournal of Bone and Mineral Research, 1999
- TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases developmentJournal of Clinical Investigation, 1999
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Clodronate decreases the frequency of skeletal metastases in women with breast cancerBone, 1996
- Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compoundJournal of Bone and Mineral Research, 1994
- Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.Journal of Clinical Investigation, 1991